Can intravenous iron therapy meet the unmet needs created by the new restrictions on erythropoietic stimulating agents?: Report from the Society for the Advancement of Blood Management 2008 Annual Meeting

Transfusion

Volumn 50, Issue 3, 2010, Pages 719-732

  Shander, Aryeh ^a   Spence, Richard K ^b   Auerbach, Michael ^b  

^a Society for the Advancement of Blood Management   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; IRON;

ANEMIA; BLOOD TRANSFUSION; CANCER PATIENT; CONFERENCE PAPER; DRUG INDICATION; DRUG LABELING; FOOD AND DRUG ADMINISTRATION; HUMAN; IRON THERAPY; MALIGNANT NEOPLASTIC DISEASE; THROMBOSIS;

ANEMIA; BLOOD TRANSFUSION; CONGRESSES AS TOPIC; HEMATINICS; HUMANS; INFUSIONS, INTRAVENOUS; IRON; NEOPLASMS;

EID: 77649222928     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2009.02492.x     Document Type: Conference Paper

References (101)

1. Besarab A. The effects of normal as compared with low hematocrit values in patients with cardiac-disease who are receiving hemodialysis and epoetin. N Engl J Med 1998 339 : 584 90.
2. Singh AK. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006 355 : 2084 98.
3. Henke M, Laszig R, Rübe C, Schäfer U, Haase KD, Schilcher B, Mose S, Beer KT, Burger U, Dougherty C, Frommhold H. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003 362 : 1255 60.
4. Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, Makhson A, Roth A, Dodwell D, Baselga J, Biakhov M, Valuckas K, Voznyi E, Liu X, Vercammen E. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005 23 : 5960 72.
5. Wright JR, Ung YC, Julian JA, Pritchard KI, Whelan TJ, Smith C, Szechtman B, Roa W, Mulroy L, Rudinskas L, Gagnon B, Okawara GS, Levine MN. Randomized, double-blind, placebo-controlled trial of erythropoietin innon-small-cell lung cancer with disease-related anemia. J Clin Oncol 2007 25 : 1027 32.
6. Bohlius J, Brillant C, Clarke M, Kluge S, Napoli M, Piper M, Rades D, Ray-Coquard I, Schmidlin K, Schumacher M, Schwarzer G, Seidenfeld J, Steensma DP, Trelle S, Untch M, Weingart O, Zwahlen M, Egger M, Engert A. Recombinant human erythropoiesis stimulating agents in cancer patients: individual patient data meta-analysis on behalf of the EPO IPD meta-analysis collaborative group. ASH Annu Meet Abstr 2008 112 : LBA 6.
7. US Food and Drug Administration. Follow-up to the January 3, 2008 communication about an ongoing safety review on erythropoiesis-stimulating agents (ESAs) epoetin alfa (marketed as Procrit, Epogen) Darbepoetin alfa (marketed as Aranesp) cited 2008 Nov 11]. Available from: URL: http://www.fda.gov/cder/drug/infopage/RHE/default.htm
8. Centers for Medicare and Medicaid Services. Proposed decision memo for erythropoiesis stimulating agents (ESAs) for non-renal disease indications (CAG-00383N). [cited 2008 Nov 11]. Available from: URL: http://www.cms.hhs.gov/ determinationprocess/downloads/id203d.pdf DH. Supplemental iron: a key to optimizing the response of cancer-related anemia to rHuEPO? Oncologist 1998 3 : 275 8.
9. Upile T, Jerjes W, Sandison A, Singh S, Rhys-Evans P, Sudhoff H, Hopper C. The direct effects of stored blood products may worsen prognosis of cancer patients; shall we transfuse or not? An explanation of the adverse oncological consequences of blood product transfusion with a testable hypothesis driven experimental research protocol. Med Hypotheses 2008 71 : 489 92.
10. Khorana AA, Francis CW, Blumberg N, Culakova E, Refaai MA, Lyman GH. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med 2008 168 : 2377 81.
11. Coyne DW, Kapoian T, Suki W, Singh AK, Moran JE, Dahl NV, Rizkala AR DRIVE Study Group. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the dialysis patients' response to IV iron with elevated ferritin (DRIVE) study. JASN 2007 18 : 975 84.
12. Larholt K, Burton T, Pashos CL, Bookhart B, Corral M, Piech CT, McKenzie R. Transfusion outcomes in erythropoiesis-stimulating agent (ESA)-treated cancer chemotherapy patients based on achieved hemoglobin (Hb) levels. J Clin Oncol 2008 26 : 6637.
13. Burton T, Larholt K, Pashos CL, Peake C, Bookhart B, Corral M, Piech CT, McKenzie R. Transfusion outcomes among oncology patients initiated with erythropoiesis-stimulating agents (ESAs) at baseline (BL) hemoglobin (Hb) of <10 versus 10-11 g/dL: observational data from the dosing and outcomes study of erythropoiesis-stimulating therapies (DOSE) registry. J Clin Oncol 2008 26 : 20637.
14. Gilmore J, Feinberg BA, Gondesen T, Jackson J, Bookhart B, McKenzie R. Hematologic and transfusion outcomes following implementation of the erythropoiesis-stimulating agent (ESA) National Coverage Determination (NCD) in Medicare cancer patients receiving chemotherapy. J Clin Oncol 2008 26 : 6548.
15. Cornes P, Coiffier B, Zambrowski JJ. Erythropoietic therapy for the treatment of anemia in patients with cancer: a valuable clinical and economic option. Curr Med Res Opin 2007 23 : 357 68.
16. Vekeman MA, Bookhart B, Duh M, McKenzie S, Lefebvre P, Piech C. Impact of limiting erythropoiesis-stimulating agent use for chemotherapy induced anemia on the United States blood supply. Transfusion 2009 49 : 895 902.
17. Whitaker BB, Sullivan M. The 2005 nationwide blood collection and utilization survey report. Washington, DC : Department of Health & Human Services 2007. [cited 2009 Jul 11]. Available from: URL: http://www.hhs.gov/ bloodsafety/2005NBCUS.pdf
18. Shander A, Hofmann A, Gombotz H, Theusinger O, Spahn D. Estimating the cost of blood: past, present and future directions. Best Pract Res Clin Anaesthesiol 2007 21 : 271 89.
19. Shander A. Financial and clinical outcomes associated with surgical bleeding complications. Surgery 2007 142 (4 Suppl S20 5.
20. Center for Medicare & Medicaid Services. Medicare and Medicaid move aggressively to encourage greater patient safety in hospitals and reduce never events. [cited 2009 Feb 3]. Available from: URL: http://www.cms.hhs.gov/apps/ media/press/release.asp?Counter=3219
21. AuBuchon J. Managing change to improve transfusion safety. Transfusion 2004 44 : 1377 83.
22. Chertow G, Mason P, Vaage-Nilson O, Ahlmen J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006 21 : 378 82.
23. Beguin Y, Maertens J, De Prijck B, Schots R, Frere P, Bonnet C, Hafraoui K, Willems E, Vanstraelen G, Lejeune M, Theunissen K, Fillet G, Baron F. Darbepoietin-Alfa and IV iron administration after autologous hematopoetic stem cell transplantation: a prospective randomized multicenter trial [abstract 54 2008 American Society of Hematology. San Francisco.
24. Amir M, Ahmad SH, Ansari Z, Dutta AK, Husain I. Total dose iron infusion during third trimester to iron deficient mothers and its influences on anemia of early infancy. Indian Pediatr 1983 20 : 335 9.
25. Ashby EC. Total dose iron dextran infusions in general surgery. Lancet 1967 2 : 807 9.
26. Stewart WK, Fleming LW, Shepherd AM. Haemoglobin and serum iron responses to periodic intravenous iron-dextran infusions during maintenance hemodialysis. Nephron 1976 17 : 121 9.
27. Bolger AP, Bartlett FR, Penston HS, O'Leary J, Pollock N, Kaprielian R, Chapman CM. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol 2006 48 : 1225 7.
28. Usmanov RI, Zueva EB, Silverberg DS, Shaked M. Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency. J Nephrol 2008 21 : 236 42.
29. Karkouti K, McCluskey SA, Ghannam M, Salpeter MJ, Quirt I, Yau TM. Intravenous iron and recombinant erythropoietin for the treatment of postoperative anemia. Can J Anaesth 2006 53 : 11 9.
30. Theusinger OM, Leyvraz PF, Schanz U, Seifert B, Spahn DR. Treatment of iron deficiency anemia in orthopedic surgery with intravenous iron: efficacy and limits: a prospective study. Anesthesiology 2007 107 : 923 7.
31. Breymann C, Richter C, Huttner C, Huch R, Huch A. Effectiveness of recombinant erythropoietin and iron sucrose vs. iron therapy only, in patients with postpartum anaemia and blunted erythropoiesis. Eur J Clin Invest 2000 30 : 154 61.
32. Van Wyck DB, Martens MG, Seid MH, Baker JB, Mangione A. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Obstet Gynecol 2007 110 (2 Pt 1 267 78.
33. Wagstrom E, Akesson A, Van Rooijen M, Larson B, Bremme K. Erythropoietin and intravenous iron therapy in postpartum anaemia. Acta Obstet Gynecol Scand 2007 86 : 957 62.
34. Agarwal R, Rizkala A, Bastani B Kaskas M, Leehey D, Besarab A. A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. Am J Nephrol 2006 26 : 445 54.
35. Gotloib L, Silverberg D, Fudin R, Shostak A. Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron. J Neprol 2006 19 : 161 7.
36. Mircescu G, Gârneať L, Čpuš C, Ursea N. Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients. Nephrol Dial Transplant 2006 21 120 4.
37. Silverberg DS, Blum M, Agbaria Z, Deutsch V, Irony M, Schwartz D, Baruch R, Yachnin T, Steinbruch S, Iaina A. The effect of IV iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period. Clin Nephrol 2001 55 : 212 9.
38. Silverberg D, Iaina A, Peer G, Kaplan E, Levi BA, Frank N, Steinbruch S, Blum M. Intravenous iron supplementation for the treatment of anemia of moderate to severe chronic renal failure patients not receiving dialysis. Am J Kidney Dis 1996 27 : 234 8.
39. Auerbach M, Witt D, Toller W, Fierstein R, Lerner R, Ballard H. Clinical use of the total dose intravenous infusion of iron dextran. J Lab Clin Med 1988 111 : 566 70.
40. Kim YT, Kim SW, Yoon BS, Cho HJ, Nahm EJ, Kim SH, Kim JH, Kim JW. Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy. Gynecol Oncol 2007 105 : 199 204.
41. Clemens J, Spivak JL. Serum immunoreactive erythropoietin during the perioperative period. Surgery 1994 115 : 510 5.
42. Dunne JR. Perioperative anemia: an independent risk factor for infection, mortality, and resource utilization in surgery. J Surg Res 2002 102 : 237 44.
43. Bierbaum SE, Callaghan JJ, Galante JO, Rubasg HE. An analysis of blood management in patients having total knee or hip arthroplasty. J Bone Joint Surg Am 1999 81 : 2 10.
44. Garcia-Erce JA, Cuenca J, Munoz M, Izuel M, Martinez AA, Herrera A, Solano VM, Martinez F. Perioperative stimulation of eryhtropoiesis with intravenous iron and erythropoietin reduces transfusion requirements in patients with hip fracture. A prospective observational study. Vox Sang 2005 88 : 235 43.
45. Munoz M, Naviera E, Seara J, Palma JH, Cuenca J, Garcia-Erce JA. Role of parenteral iron in transfusion requirements after total hip replacement. Transfus Med 2006 16 : 137 42.
46. Eschbach JW. Iron requirements in erythropoietin therapy. Best Pract Res Clin Haematol 2005 18 : 347 61.
47. National Kidney Foundation. KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006 47 (3 Suppl S1 146.
48. Auerbach M. Should intravenous iron be the standard of care in oncology J Clin Oncol 2008 26 : 1579 81.
49. Schaefer RM, Schaefer L. Management of iron substitution during r-HuEPO therapy in chronic renal failure patients. Erythropoiesis 1992 3 : 71 5.
50. Nyvad O, Danielson H, Madsen S. Intravenous iron-sucrose complex to reduce epoetin demand in dialysis patients. Lancet 1994 344 : 1305 6.
51. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron administration. Am J Kidney Dis 1995 26 : 41 6.
52. Sunder-Plassman G, Horl WH. Optimizing low dose r-HuEPO combined with low dose IV iron therapy in hemodialysis patients. J Am Soc Nephrol 1994 5 : 478.
53. Ahsan N, Groff JA, Waybill MA. Efficacy of bolus intravenous iron dextran treatment in peritoneal dialysis patients receiving recombinant human erythropoietin. Adv Perit Dialy 1996 12 : 161 6.
54. Silverberg DS, Blum M, Agbaria Z, Peer G, Kaplan E, Iaina A. Intravenous ferric saccharate as an iron supplement in dialysis patients. Nephron 1996 72 : 413 7.
55. Sepandj F, Jindall K, West M, Hirsch D. Economic appraisal of maintenance parenteral iron administration in the treatment of anemia in chronic hemodialysis patients. Nephrol Dial Transplant 1996 11 : 319 22.
56. Taylor JE, Peat N, Porter C, Morgan AG. Regular low-dose intravenous iron therapy improves response to erythropoietin in hemodialysis patients. Nephrol Dial Transplant 1996 1 : 1079 83.
57. Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996 50 : 1694 9.
58. Besarab A. Resolving the paradigm crisis in intravenous iron and erythropoietin management. Kidney Int Suppl 2006 : S13 8.
59. Auerbach M, Ballard H, Trout JR, McIlwain M, Ackerman A, Bahrain H, Balan S, Barker L, Rana J. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 2004 22 : 1301 7.
60. Martelli O, Garassino M, Sacchetta S, Caristo R, Zivi A, Cerbone L, Mancuso A. Darbepoetin alfa administered every three weeks (Q3W) in anemic cancer patients receiving chemotherapy (CT). Anticancer Res 2008 28 : 1767 71.
61. Osterborg A, Brandberg Y, Molostova V, Iosava G, Abdulkadyrov K, Hedenus M, Messinger D Epoetin Beta Hematology Study Group. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies. J Clin Oncol 2002 20 : 2486 94.
62. Hedenus M, Birgegard G, Näsman P, Ahlberg L, Karlsson T, Lauri B, Lundin J, Lärfars G, Osterborg A. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia 2008 22 : 462.
63. Rizzo JD, Somerfield MR, Hagerty KL, Seidenfeld J, Bohlius J, Bennett CL, Cella DF, Djulbegovic B, Goode MJ, Jakubowski AA, Rarick MU, Regan DH, Lichtin AE. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood 2008 111 : 25 41.
64. Gilreath JA, Sageser DS, Jorgenson JA, Rogers GM. Establishing an anemia clinic for optimal erythropoietic-stimulating agent use in hematology-oncology patients. J Natl Compr Canc Netw 2008 6 : 577 84.
65. Shord S, Hamilton JM, Cuellar S. Parenteral iron with erythropoiesis-stimulating agents for chemotherapy induced anemia. J Oncol Pharm Pract 2008 14 : 5 22.
66. Henry DH, Dahl NV, Auerbach M, Tchekmedyian S, Laufman LR. Intravenous iron optimizes the response to epoeitin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007 12 : 231 42.
67. Bastit L, Vadebroek A, Altintas S, Gaede B, Pinter T, Suto T, Mossman T, Smith K, Vansteenkiste J. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alfa administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 2008 26 : 1611 8.
68. Pedrazzoli P, Farris A, Del Prete S, Del Gaizo F, Ferrari D, Bianchessi C, Colucci G, Desogus A, Gamucci T, Pappalardo A, Fornarini G, Pozzi P, Fabi A, Labianco R, Di Costanzo F, Secondino S, Crucitta E, Apolloni F, Del Santo A, Siena S. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alfa. J Clin Oncol 2008 26 : 1619 25.
69. Auerbach M, Silberstein P, Webb T, Averyanova S, Ciuleanu T, Cam L, Shao J, Lillie T. Darbepoetin alfa 500 mcg or 300 mcg once very three weeks with or without iron in patients with chemotherapy induced anemia [abstract LBA9]. Ann Oncol 2008 19 (Suppl 8 viii1 4.
70. Glaspy J. The development of erythropoeitic agents in oncology. Expert Opin Emerg Drugs 2005 10 : 553 67.
71. Munoz M, Campos A, Garcia-Erce JA. Intravenous iron in colorectal cancer surgery. Semin Hematol 2006 43 (6 Suppl S36 8.
72. Campos A, Sevilla L, Baca JJ, Romero A, Ramirez G, Munoz M. Perioperative iron therapy and transfusion requirements in patients undergoing surgery for colon cancer. Transfus Alternat Transfus Med 2005 7 : 96.
73. Braga M, Gianotti L, Vignali A, Gianotti L, Vignali A, Gentilini O, Servida P, Bordignon C, Di Carlo V. Evaluation of recombinant human erythropoietin to facilitate autologous blood donation before surgery in anemia patients with cancer of the gastrointestinal tract. Br J Surg 1995 82 : 1637 40.
74. Kosmadakis N, Messaris E, Maris A, Katsaragakis S, Leandros E, Konstadoulakis MM, Androulakis G. Perioperative erythropoietin administration in patients with gastrointestinal tract cancer: prospective randomized double blind study. Ann Surg 2003 237 : 417 21.
75. James AH, Patel ST, Watson W, Zaidi QR, Mangione A, Goss TF. An assessment of medical resource utilization and hospitalization cost associated with a diagnosis of anemia in women with obstetrical bleeding in the United States. J Womens Health (Larchmt) 2008 17 : 1279 84.
76. Huch R, Breyman C. Anemia in pregnancy and the pueriperium. 2nd ed. Bremen : UNI-MED Science Verlag 2006.
77. Broche DE, Gay C, Armand-Branger S, GRangesse L, Terzibachian JJ. Acute postpartum anemia. Clinical practice and interest of intravenous iron. Gynecol Obstet Fertil 2004 : 32 : 613 9.
78. Komolafe JO, Kuti O, Ijadunola KT, Ogunniyi SO. A comparative study between intramuscular iron dextran and oral ferrous sulphate in the treatment of iron deficiency anaemia in pregnancy. J Obstet Gynaecol 2003 23 : 628 31.
79. Goetsch AT, Moore CV, Minnich V. Observations on the effects of massive doses of iron given intravenously to patients with hypochromic anemia. Blood 1946 1 : 129 42.
80. Auerbach M, Coyne D, Ballard H. Intravenous iron: from anathema to standard of care. Am J Hemat 2008 83 : 580 8.
81. INFeD® [package insert]. Corona (CA): Watson Pharmaceuticals 1998.
82. Dexferrum® [package insert]. Shirley (NY): American Regent, Inc. 1998.
83. Auerbach M, Ballard H, Glaspy J. Clinical update: intravenous iron for anemia. Lancet 2007 369 : 1502 4.
84. Chertow G, Mason P, Vaage-Nilsen O, Ahlmen J. On the relative safety of parenteral iron formulations. Nephrol Dial Transplant 2004 19 : 1571 5.
85. Feraheme [package insert]. Lexington (MA): AMAG Pharmaceuticals 2009.
86. Danielson B. Structure, chemistry, and pharmacokinetics of intravenous iron. J Am Soc Nephrol 2004 15 (2 Suppl S93 8.
87. Ferrlecit® [package insert]. Corona (CA): Watson Pharmaceuticals 2001.
88. Venofer® [package insert]. Shirley (NY): American Regent, Inc. 2005.
89. Charytan C, Schwenk M, Al-Saloum M, Spinowitz B. Safety of iron sucrose in hemodialysis patients intolerant to other parenteral iron products. Nephron Clin Pract 2004 96 : c63 6.
90. Michael B, Coyne DW, Fishbane S, Folkert V, Lynn R, Nissenson AR, Agarwal R, Eschbach JW, Fadem SZ, Trout JR, Strobos J, Warnock DG Ferrlecit Publication Committee. Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran. Kidney Int 2002 61 : 1830 9.
91. Kudasheva DS, Lai J, Ulman A, Cowman MK. Structure of carbohydrate-bound polynuclear iron oxyhydroxide nanoparticles in parenteral formulations. J Inorg Biochem 2004 98 : 1757 69.
92. Van Wyck DB. Labile iron: manifestations and clinical implications. J Am Soc Nephrol 2004 15 (2 Suppl S107 11.
93. Jain A, Bastani B. Safety profile of high dose ferric gluconate in patients with severe chronic renal insufficiency. J Nephrol 2002 15 : 681 3.
94. Blaustein DA, Schwenk MH, Chattopadhyay J, Singh H, Daoui R, Gadh R, Avram MM. Safety and efficacy of an accelerated iron sucrose dosing regimen in patients with chronic kidney disease. Kidney Int 2003 87 : S72 7.
95. Auerbach M. Ferumoxytol as a newer, safer, easier to administer intravenous iron: yes or no? Am J Kidney Dis 2008 52 : 826 9.
96. Bishu K, Agarwal R. Acute injury with intravenous iron and concerns regarding long-term safety. Clin J Am Soc Nephrol 2006 1 (1 Suppl S19 23.
97. Faich G, Strobos J. Sodium ferric gluconate in sucrose: safer intravenous iron therapy than iron dextrans. Am J Kidney Dis 1999 33 : 464 70.
98. Bailie GR, Clark JA. Hypersensitivity reactions and deaths associated with intravenous iron preparations. Nephrol Dial Transplant 2005 20 : 1443 9.
99. Moniem K, Bhandari S. Tolerability and efficacy of parenteral iron therapy in hemodialysis patients, a comparison of preparations. Transfusion Transfus Alternat Transfus Med 2007 9 : 37 42.
100. Sav T, Tokgoz B, Sipahioglu MH, Deveci M, Sari I, Oymak O, Utas C. Is there a difference between the allergic potentials of iron sucrose and low molecular weight iron dextran Ren Fail 2007 29 : 423 6.
101. Auerbach M, Goodnough T, Picard D, Maniatis A. The role of intravenous iron in anemia management and transfusion avoidance. Transfusion 2008 48 : 988 1000. (Pubitemid 351614910)